DKP102

DKP102 is an improved new drug (개량신약) being developed by Dongkwang for the treatment of hyperlipidemia. In the South Korean regulatory framework, an 'improved new drug' typically refers to a product that offers an incremental improvement over an existing drug, such as a new formulation, a fixed-dose combination, or a modified-release profile, intended to enhance safety, efficacy, or patient convenience. While DKP102 is identified as a small molecule, the specific active pharmaceutical ingredients and its precise mechanism of action have not been publicly disclosed by the developer. As of 2021, the candidate was in the preclinical or early development stage.